Development and optimization of a high-throughput assay to measure neutralizing antibodies against clostridium difficile binary toxin

Clinical and Vaccine Immunology

Volumn 21, Issue 5, 2014, Pages 689-697

  Xie, Jinfu ^a   Horton, Melanie ^a   Zorman, Julie ^a   Antonello, Joseph M ^a   Zhang, Yuhua ^a   Arnold, Beth A ^a   Secore, Susan ^a   Xoconostle, Rachel ^a   Miezeiewski, Matthew ^b   Wang, Su ^a   Price, Colleen E ^a   Thiriot, David ^a   Goerke, Aaron ^a,c   Gentile, Marie Pierre ^a,c   Skinner, Julie M ^a   Heinrichs, Jon H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Eurofins Medinet Inc   (Germany)

^c GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; NEUTRALIZING ANTIBODY; ACTIN-SPECIFIC ADP-RIBOSYLTRANSFERASE, CLOSTRIDIUM; BACTERIAL PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CELL DENSITY; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG DOSE COMPARISON; DRUG EFFICACY; HAMSTER; HAPLORHINI; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; INCUBATION TIME; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; SENSITIVITY AND SPECIFICITY; TOXIN ANALYSIS; ANIMAL; BLOOD; CHLOROCEBUS AETHIOPS; IMMUNOLOGY; PROCEDURES; RHESUS MONKEY; VERO CELL LINE;

ADP RIBOSE TRANSFERASES; ANIMALS; ANTIBODIES, NEUTRALIZING; BACTERIAL PROTEINS; CERCOPITHECUS AETHIOPS; CRICETINAE; HIGH-THROUGHPUT SCREENING ASSAYS; MACACA MULATTA; VERO CELLS;

EID: 84899706771     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00038-14     Document Type: Article

References (37)

1. Cartman ST, Heap JT, Kuehne SA, Cockayne A, Minton NP. 2010. The emergence of 'hypervirulence' in Clostridium difficile. Int. J. Med. Microbiol. 300:387-395. http://dx.doi.org/10.1016/j.ijmm.2010.04.008.
2. McDonald LC, Killgore GE, Thompson A, Owens RC, Jr, Kazakova SV, Sambol SP, Johnson S, Gerding DN. 2005. An epidemic, toxin genevariant strain of Clostridium difficile. N. Engl. J. Med. 353:2433-2441. http://dx.doi.org/10. 1056/NEJMoa051590. (Pubitemid 41770164)
3. Giesemann T, Egerer M, Jank T, Aktories K. 2008. Processing of Clostridium difficile toxins. J. Med. Microbiol. 57:690-696. http://dx.doi.org/10.1099/jmm.0.47742-0. (Pubitemid 351842059)
4. Rupnik M, Pabst S, Rupnik M, von Eichel-Streiber C, Urlaub H, Söling HD. 2005. Characterization of the cleavage site and function of resulting cleavage fragments after limited proteolysis of Clostridium difficile toxin B (TcdB) by host cells. Microbiology 151:199-208. http://dx.doi.org/10.1099/mic.0. 27474-0. (Pubitemid 40214335)
5. Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP. 2010. The role of toxin A and toxin B in Clostridium difficile infection. Nature 467:711-713. http://dx.doi.org/10.1038/nature09397.
6. Barth H, Blocker D, Behlke J, Bergsma-Schutter W, Brisson A, Benz R, Aktories K. 2000. Cellular uptake of Clostridium botulinum C2 toxin requires oligomerization and acidification. J. Biol. Chem. 275:18704-18711. http://dx.doi.org/10.1074/jbc.M000596200. (Pubitemid 30422828)
7. Barth H, Aktories K, Popoff MR, Stiles BG. 2004. Binary bacterial toxins: biochemistry, biology, and applications of common Clostridium and Bacillus proteins. Microbiol. Mol. Biol. Rev. 68:373-402, table of contents. http://dx.doi.org/10.1128/MMBR.68.3.373-402.2004.
8. Aktories K, Reuner KH, Presek P, Bärmann M. 1989. Botulinum C2 toxin treatment increases the G-actin pool in intact chicken cells: a model for the cytopathic action of actin-ADP-ribosylating toxins. Toxicon 27:989-993. http://dx.doi.org/10.1016/0041-0101(89)90149-9. (Pubitemid 19226952)
9. Kaiser E, Kroll C, Ernst K, Schwan C, Popoff M, Fischer G, Buchner J, Aktories K, Barth H. 2011. Membrane translocation of binary actin-ADP- ribosylating toxins from Clostridium difficile and Clostridium perfringens is facilitated by cyclophilinAand Hsp90. Infect. Immun. 79:3913-3921. http://dx.doi.org/10.1128/IAI.05372-11.
10. Papatheodorou P, Carette JE, Bell GW, Schwan C, Guttenberg G, Brummelkamp TR, Aktories K. 2011. Lipolysis-stimulated lipoprotein receptor (LSR) is the host receptor for the binary toxin Clostridium difficile transferase (CDT). Proc. Natl. Acad. Sci. U. S. A. 108:16422-16427. http://dx.doi.org/10.1073/pnas. 1109772108.
11. Geric B, Carman RJ, Rupnik M, Genheimer CW, Sambol SP, Lyerly DM, Gerding DN, Johnson S. 2006. Binary toxin-producing, large clostridial toxin-negative Clostridium difficile strains are enterotoxic but do not cause disease in hamsters. J. Infect. Dis. 193:1143-1150. http://dx.doi.org/10.1086/501368.
12. Schwan C, Stecher B, Tzivelekidis T, van Ham M, Rohde M, Hardt WD, Wehland J, Aktories K. 2009. Clostridium difficile toxin CDT induces formation of microtubule-based protrusions and increases adherence of bacteria. PLoS Pathog. 5:e1000626. http://dx.doi.org/10.1371/journal.ppat.1000626.
13. Bacci S, Molbak K, Kjeldsen MK, Olsen KE. 2011. Binary toxin and death after Clostridium difficile infection. Emerg. Infectious Dis. 17:976-982. http://dx.doi.org/10.3201/eid/1706.101483.
14. Barbut F, Gariazzo B, Bonné L, Lalande V, Burghoffer B, Luiuz R, Petit JC. 2007. Clinical features of Clostridium difficile-associated infections and molecular characterization of strains: results of a retrospective study, 2000-2004. Infect. Control Hosp. Epidemiol. 28:131-139. http://dx.doi.org/10. 1086/511794. (Pubitemid 46374152)
15. Barbut F, Decré D, Lalande V, Burghoffer B, Noussair L, Gigandon A, Espinasse F, Raskine L, Robert J, Mangeol A, Branger C, Petit JC. 2005. Clinical features of Clostridium difficile-associated diarrhoea due to binary toxin (actin-specific ADP-ribosyltransferase)-producing strains. J. Med. Microbiol. 54:181-185. http://dx.doi.org/10.1099/jmm.0.45804-0. (Pubitemid 40868005)
16. Hensgens MP, Kuijper EJ. 2013. Clostridium difficile infection caused by binary toxin-positive strains. Emerg. Infect. Dis. 19:1539-1540. http://dx.doi.org/10.3201/eid1909.110814.
17. Walk ST, Micic D, Jain R, Lo ES, Trivedi I, Liu EW, Almassalha LM, Ewing SA, Ring C, Galecki AT, Rogers MA, Washer L, Newton DW, Malani PN, Young VB, Aronoff DM. 2012. Clostridium difficile ribotype does not predict severe infection. Clin. Infect. Dis. 55:1661-1668. http://dx.doi.org/10.1093/cid/ cis786.
18. Kelly CP, LaMont JT. 2008. Clostridium difficile-more difficult than ever. N. Engl. J. Med. 359:1932-1940. http://dx.doi.org/10.1056/NEJMra0707500.
19. Crook DW, Walker AS, Kean Y, Weiss K, Cornely OA, Miller MA, Esposito R, Louie TJ, Stoesser NE, Young BC, Angus BJ, Gorbach SL, Peto TE, Study 003/004 Teams. 2012. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin. Infect. Dis. 55(Suppl 2):S93-S103. http://dx.doi.org/10.1093/cid/cis499.
20. Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, Nichol G, Thomas WD, Jr, Leney M, Sloan S, Hay CA, Ambrosino DM. 2010. Treatment with monoclonal antibodies against Clostridium difficile toxins. N. Engl. J. Med. 362:197-205. http://dx.doi.org/10.1056/NEJMoa0907635.
21. Foglia G, Shah S, Luxemburger C, Pietrobon PJ. 2012. Clostridium difficile: development of a novel candidate vaccine. Vaccine 30:4307-4309. http://dx.doi.org/10.1016/j.vaccine.2012.01.056.
22. Tian JH, Fuhrmann SR, Kluepfel-Stahl S, Carman RJ, Ellingsworth L, Flyer DC. 2012.Anovel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models. Vaccine 30:4249-4258. http://dx.doi.org/10.1016/j.vaccine.2012.04.045.
23. Heinrichs JH, Bodmer JL, Secore SL, Goerke AR, Caro-Aguilar I, Gentile MP, Horton MS, Miezeiewski MR, Skinner JM, Sondermeijer PJA, Subramanian S, van der Heijden-Liefkens KHA, Wang S, Xie J, Xoconostle RF, Zorman JK. August 2013. Vaccines against Clostridium difficile comprising recombinant toxins. Patent WO2013112867.
24. Gülke I, Pfeifer G, Liese J, Fritz M, Hofmann F, Aktories K, Barth H. 2001. Characterization of the enzymatic component of the ADP- ribosyltransferase toxin CDTa from Clostridium difficile. Infect. Immun. 69:6004-6011. http://dx.doi.org/10.1128/IAI.69.10.6004-6011.2001. (Pubitemid 32885159)
25. Xie J, Zorman J, Indrawati L, Horton M, Soring K, Antonello JM, Zhang Y, Secore S, Miezeiewski M, Wang S, Kanavage T, Skinner JM, Rogers I, Bodmer JL, Heinrichs JH. 2013. Development and optimization of a novel assay to measure neutralizing antibodies against Clostridium difficile toxins. Clin. Vaccine Immunol. 20:9. http://dx.doi.org/10.1128/CVI.00516-12.
26. Sundriyal A, Roberts AK, Ling R, McGlashan J, Shone CC, Acharya KR. 2010. Expression, purification and cell cytotoxicity of actin-modifying binary toxin from Clostridium difficile. Protein Expr. Purif. 74:42-48. http://dx.doi.org/10. 1016/j.pep.2010.04.014.
27. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, Bourgault AM, Nguyen T, Frenette C, Kelly M, Vibien A, Brassard P, Fenn S, Dewar K, Hudson TJ, Horn R, René P, Monczak Y, Dascal A. 2005. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl. J. Med. 353:2442-2449. http://dx.doi.org/10.1056/NEJMoa051639. (Pubitemid 41770165)
28. Black SR, Weaver KN, Jones RC, Ritger KA, Petrella LA, Sambol SP, Vernon M, Burton S, Garcia-Houchins S, Weber SG, Lavin MA, Gerding D, Johnson S, Gerber SI. 2011. Clostridium difficile outbreak strain BI is highly endemic in Chicago area hospitals. Infect. Control Hosp. Epidemiol. 32:897-902. http://dx.doi.org/10.1086/661283.
29. Goldenberg SD French GL. 2011. Lack of association of tcdC type and binary toxin status with disease severity and outcome in toxigenic Clostridium difficile. J. Infect. 62:355-362. http://dx.doi.org/10.1016/j.jinf.2011.03.001.
30. Yen FT, Masson M, Clossais-Besnard N, André P, Grosset JM, Bougueleret L, Dumas JB, Guerassimenko O, Bihain BE. 1999. Molecular cloning of a lipolysis-stimulated remnant receptor expressed in the liver. J. Biol. Chem. 274:13390-13398. http://dx.doi.org/10.1074/jbc.274.19.13390.
31. Mesli S, Javorschi S, Berard AM, Landry M, Priddle H, Kivlichan D, Smith AJ, Yen FT, Bihain BE, Darmon M. 2004. Distribution of the lipolysis stimulated receptor in adult and embryonic murine tissues and lethality of LSR-/- embryos at 12.5 to 14.5 days of gestation. Eur. J. Biochem. 271:3103-3114. http://dx.doi.org/10.1111/j.1432-1033.2004.04223.x. (Pubitemid 38998680)
32. Masuda S, Oda Y, Sasaki H, Ikenouchi J, Higashi T, Akashi M, Nishi E, Furuse M. 2011. LSR defines cell corners for tricellular tight junction formation in epithelial cells. J. Cell Sci. 124:548-555. http://dx.doi.org/10. 1242/jcs.072058.
33. Nagahama M, Umezaki M, Oda M, Kobayashi K, Tone S, Suda T, Ishidoh K, Sakurai J. 2011. Clostridium perfringens iota-toxin b induces rapid cell necrosis. Infect. Immun. 79:4353-4360. http://dx.doi.org/10.1128/IAI.05677-11.
34. Richard JF, Mainguy G, Gibert M, Marvaud JC, Stiles BG, Popoff MR. 2002. Transcytosis of iota-toxin across polarized CaCo-2 cells. Mol. Microbiol. 43:907-917. http://dx.doi.org/10.1046/j.1365-2958.2002.02806.x. (Pubitemid 34415715)
35. Papatheodorou P, Hornuss D, Nölke T, Hemmasi S, Castonguay J, Picchianti M, Aktories K. 2013. Clostridium difficile binary toxin CDT induces clustering of the lipolysis-stimulated lipoprotein receptor into lipid rafts. mBio. 4(3):e00244 -13. http://dx.doi.org/10.1128/mBio.00244-13.
36. Carman RJ, Stevens AL, Lyerly MW, Hiltonsmith MF, Stiles BG, Wilkins TD. 2011. Clostridium difficile binary toxin (CDT) and diarrhea. Anaerobe 17: 161-165. http://dx.doi.org/10.1016/j.anaerobe.2011.02.005.
37. Kyne L, Warny M, Qamar A, Kelly CP. 2000. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N. Engl. J. Med. 342:390-397. http://dx.doi.org/10.1056/NEJM200002103420604. (Pubitemid 30084537)